All In Biotech

Drug Trial Radar · NCT04614103

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (TIL or LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

170

Planned (sponsor's estimate)

Start

May 7, 2021

Primary completion

Dec 2030

Study completion Dec 2031

Sponsor

Lead sponsor
Iovance Biotherapeutics, Inc.Industry
Sponsor type
Industry
First posted
Nov 3, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer

Conditions

  • Metastatic Non Small Cell Lung Cancer

Interventions

  • LN-145Biological

    A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, patient is infused with autologous TIL (LN-145), followed by IL-2.

  • LN-145Biological

    A tumor sample is obtained by image-guided core biopsy from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, patient is infused with autologous TIL (LN-145) followed by IL-2.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response RateTime frame: Up to 60 months

Locations

71 sites in 12 countries. Site status is shown where the registry gives one.

  • Banner Health MD Anderson

    Gilbert, Arizona · Recruiting

  • Sylvester Comprehensive Cancer Center

    Miami, Florida · Active not recruiting

  • H Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida · Recruiting

  • Rush University Medical Center

    Chicago, Illinois · Active not recruiting

  • University of Illinois Hospital & Health Sciences System

    Chicago, Illinois · Active not recruiting

  • Advocate Aurora Health

    Park Ridge, Illinois · Recruiting

  • University of Louisville

    Louisville, Kentucky · Recruiting

  • University of Maryland

    Baltimore, Maryland · Active not recruiting

  • Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • University of Minnesota

    Minneapolis, Minnesota · Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska · Recruiting

  • MD Anderson Cooper

    Camden, New Jersey · Recruiting

  • New York University Langone Medical Center

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • University of North Carolina

    Chapel Hill, North Carolina · Recruiting

  • Novant Health - Winston-Salem

    Winston-Salem, North Carolina · Active not recruiting

  • Sanford Roger Maris Cancer Center

    Fargo, North Dakota · Recruiting

  • University of Cincinnati Medical Center

    Cincinnati, Ohio · Recruiting

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

  • Oregon Health and Science University

    Portland, Oregon · Recruiting

  • Allegheny General Hospital

    Natrona Heights, Pennsylvania · Recruiting

  • Sanford Cancer Center

    Sioux Falls, South Dakota · Recruiting

  • Avera Medical Group Cancer Institute

    Sioux Falls, South Dakota · Active not recruiting

  • University of Tennessee Medical Center

    Knoxville, Tennessee · Recruiting

  • Baptist Cancer Center

    Memphis, Tennessee · Recruiting

  • VCU Medical Center (Virginia Commonwealth University)

    Richmond, Virginia · Recruiting

  • Seattle Cancer Care Alliance

    Seattle, Washington · Recruiting

  • St. Vincent's Hospital

    Darlinghurst, New South Wales, Australia · Recruiting

  • Westmead Hospital

    Westmead, New South Wales, Australia · Recruiting

  • Hollywood Private Hospital Ramsay

    Nedlands, Western Australia, Australia · Recruiting

  • Centre Hospitalier de l'Universite de Montreal (CHUM)

    Montreal, Canada · Recruiting

  • Institut Paoli Calmettes

    Marseille, France · Recruiting

  • CHU Nantes

    Nantes, France · Recruiting

  • CHU Nice

    Nice, France · Recruiting

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, France · Recruiting

  • CHRU de Poitiers La Miletrie

    Poitiers, France · Recruiting

  • Gustave Roussy Cancer Campus

    Villejuif, France · Recruiting

  • Charite- Universitätsklinikum Berlin

    Berlin, Germany · Recruiting

  • Universitätsklinikum Carl Gustav Carus, MK I

    Dresden, Germany · Recruiting

  • Universitätsklinikum Frankfurt

    Frankfurt, Germany · Recruiting

Showing 40 of 71 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.